Thrombocytopenia: History and Discovery

Thrombocytopenia simply means a low platelet count — too few of the tiny clotting cells that plug damaged blood vessels — and it shows itself as easy bruising, pinpoint skin spots, nosebleeds, and, when severe, dangerous bleeding. Its history is really two intertwined stories. The first is the discovery of the platelet itself: a microscopic blood particle so small it was repeatedly seen and dismissed before the Italian pathologist Giulio Bizzozero, in 1882, named it and proved it was the body's first responder to a wound. The second is the centuries-long effort to understand why platelets disappear — a puzzle that runs from Paul Gottlieb Werlhof's 1735 description of a mysterious bleeding disease, through William Harrington's astonishing 1950–51 experiment on his own body that proved the immune system can attack platelets, to the 1994 discovery of thrombopoietin, the hormone that tells the marrow how many platelets to make. This page traces that history with care: every named discoverer, date, and "first" below has been checked against the medical literature.

Table of Contents

  1. What Thrombocytopenia Is
  2. Finding the Platelet: From Specks to a Named Cell
  3. Bizzozero and the Birth of the Platelet (1882)
  4. Werlhof's Disease and the Riddle of Purpura (1735)
  5. Counting Platelets and Connecting Them to Bleeding
  6. Harrington's Self-Experiment: Proving ITP Is Immune (1950–51)
  7. Sorting Out the Many Causes
  8. Thrombopoietin and the Modern Era (1994–today)
  9. Legacy and What the History Teaches
  10. Research Papers and References
  11. Connections

What Thrombocytopenia Is

Platelets, or thrombocytes, are the smallest of the blood's three formed elements — far smaller than red cells or white cells — and they are not really whole cells at all but fragments shed from giant marrow cells called megakaryocytes. When a blood vessel is cut, platelets are the first thing to arrive: they stick to the wound, clump together, and form the initial plug that stops bleeding while the slower fibrin clot is built. A healthy adult normally carries roughly 150,000 to 450,000 platelets per microliter of blood. Thrombocytopenia — from the Greek thrombo- (clot), cyto- (cell), and -penia (poverty or lack) — is the medical word for having too few of them.

The consequences follow directly from the platelet's job. With a mildly low count a person may notice nothing; as the number falls, easy bruising appears, then the characteristic rash of petechiae (tiny red or purple pinpoints, especially on the lower legs) and larger purpura, then bleeding gums, nosebleeds, and heavy menstrual periods. At very low counts the risk becomes spontaneous internal bleeding. These visible signs — the bruises and the purple spots — were described centuries before anyone knew what a platelet was, which is why the history of thrombocytopenia begins with the disease long before it reaches the cell.

Crucially, a low platelet count is a finding, not a single disease. Platelets can fall because the marrow makes too few (marrow failure, chemotherapy, certain infections), because they are destroyed too fast (immune attack, drug reactions, the consumption of clotting in disseminated intravascular coagulation), or because they are pooled away in an enlarged spleen. Untangling those very different mechanisms — which look identical at the bedside as "bruising and bleeding" — is the thread that ties this whole history together.

Back to Table of Contents

Finding the Platelet: From Specks to a Named Cell

For most of the history of microscopy the platelet was a nuisance — a scatter of tiny granules in a blood smear that observers noticed, puzzled over, and mostly explained away as debris, clumped protein, or fragments of other cells. Antonie van Leeuwenhoek and later microscopists in the seventeenth and eighteenth centuries described the red corpuscles in detail, but the platelet's small size and tendency to clump the instant blood leaves the body made it extraordinarily easy to overlook or to mistake for an artifact. Through the early nineteenth century a number of investigators — among them William Addison, George Gulliver, and Alfred Donné — recorded small bodies or "globulins" in blood that, in hindsight, were almost certainly platelets, but none established what they were.

The German anatomist Max Schultze brought the picture into sharper focus in 1865. In a study chiefly concerned with white blood cells, Schultze gave the first genuinely accurate microscopic description of the small granular masses, noted that they were a normal and constant component of blood rather than an artifact, and observed that they tended to gather into clumps. He stopped short, however, of declaring them an independent formed element or working out their function. That decisive step — recognizing the platelet as a distinct third cell of the blood with a job of its own — belongs to Giulio Bizzozero a generation later.

It is worth pausing on why this took so long, because it shapes everything that follows. A platelet is not only tiny; it is exquisitely reactive. The moment blood is drawn, platelets activate, change shape, and stick together in tangled heaps, destroying exactly the orderly appearance a microscopist would need to study individual particles. Bizzozero's breakthrough came precisely because he found a way to watch platelets inside living, flowing circulation rather than in a static, already-clotting drop on a slide.

Back to Table of Contents

Bizzozero and the Birth of the Platelet (1882)

The platelet was identified and named as the third formed element of the blood by the Italian pathologist Giulio Bizzozero in 1882. Working at the University of Turin, Bizzozero used a technique of intravital microscopy — observing the small blood vessels of living animals (notably the mesentery and the wing membrane) under the microscope while the blood was still circulating — which let him see platelets behaving naturally instead of as a clumped mess on a slide. He recognized them as a population of small bodies entirely distinct from both red cells and white cells, and he gave them the name by which they are still known in Italian, piastrine ("little plates"), rendered in English as blood platelets.

Bizzozero did far more than name them. In a series of careful experiments he showed that platelets are the first component of the blood to adhere to a site of vessel injury and to each other — the opening act of hemostasis — and that this platelet plug forms before, and serves as the scaffold for, the fibrin that follows. He observed the same sequence in the test tube, watching platelets be the first blood element to coat a thread that then became wrapped in fibrin. In doing so he tied the new cell directly to both hemostasis (the normal stopping of bleeding) and thrombosis (unwanted clotting inside vessels), the two faces of platelet biology that dominate the field to this day. The historical review by Ribatti and Crivellato, "Giulio Bizzozero and the discovery of platelets" (2007), documents this work and Bizzozero's broader role as a founder of modern hematology and histology.

The significance for thrombocytopenia is immediate and profound: once the platelet was a defined cell whose business was clotting, the centuries-old "bleeding diseases" of unexplained bruising and purpura finally had a physical object to be measured against. A patient who bruised and bled for no obvious reason might simply not have enough of Bizzozero's little plates. Within a year, that idea would be tested.

Back to Table of Contents

Werlhof's Disease and the Riddle of Purpura (1735)

Long before the platelet was known, physicians described the disease that low platelets cause. The most influential early account belongs to the German physician and court doctor Paul Gottlieb Werlhof (1699–1767), who in 1735 described a striking bleeding illness he named morbus maculosus haemorrhagicus — the "spotted hemorrhagic disease." His classic case was a young woman who, after a feverish illness, bled heavily from the nose and mouth and broke out in skin discolorations that he recorded as "partly black, partly violaceous or purple." The illness that came to bear his name, Werlhof's disease, is what we now call immune (idiopathic) thrombocytopenic purpura, or ITP.

Werlhof, of course, had no concept of a platelet and no microscope capable of settling the question; he described a pattern of symptoms — the purpura, the spontaneous bleeding, the tendency of some patients to recover and others to relapse — with the clinical acuity of his era. For roughly the next century and a half, "Werlhof's disease" remained a purely clinical label for an unexplained bleeding tendency, lumped together with other purpuras and hemorrhagic states whose causes were entirely unknown. The name endured well into the twentieth century and is still occasionally encountered in older European texts.

It is fair to note that Werlhof was not the very first to describe purpuric bleeding — accounts of "the purples" appear earlier, and historians sometimes cite cases attributed to Amatus Lusitanus and others in the sixteenth and seventeenth centuries. Werlhof's 1735 description, however, is the one that fixed the disease in the medical imagination and gave it a durable name, which is why the modern historical reviews of ITP, such as those by Stasi and Newland and by Liebman, take him as the conventional starting point.

Back to Table of Contents

Counting Platelets and Connecting Them to Bleeding

Bizzozero's 1882 work named the cell; the next task was to count it and to prove that a shortage of it caused the old bleeding diseases. This connection was made with remarkable speed. Within roughly a year of Bizzozero's description, investigators — the work is commonly credited around 1883, with the French physician Georges Hayem prominent among those who developed early platelet-counting methods and studied platelets in disease — established that the purpura and bleeding of conditions like Werlhof's disease were accompanied by a marked reduction in the number of circulating platelets. The abstract "spotted hemorrhagic disease" now had a measurable cause: too few platelets.

Reliable platelet counting was itself a hard-won technical achievement. Platelets are small, nearly colorless, and clump the moment blood is shed, so the earliest counts were difficult and inconsistent; methods improved through the work of Hayem and later observers who devised better diluting fluids and counting chambers to keep the platelets separate and visible. By the early twentieth century a quantitative platelet count had become part of the laboratory assessment of bleeding, and the modern term thrombocytopenia — literally a poverty of clotting cells — came into use to name the finding directly, gradually displacing the older eponym "Werlhof's disease" for the laboratory abnormality.

This was a turning point in the whole field. A bleeding patient could now be sorted by a number. A very low count explained the bleeding; a normal count pointed the search elsewhere, toward clotting-factor problems such as hemophilia or von Willebrand disease. Counting, in other words, split what had been one vague category of "hemorrhagic diseases" into the distinct disorders recognized today — but it still could not say why the platelets were low. That deeper question, at least for Werlhof's disease, would not be answered for another half-century, and the answer would come from one of the boldest experiments in the history of medicine.

Back to Table of Contents

Harrington's Self-Experiment: Proving ITP Is Immune (1950–51)

By the mid-twentieth century, doctors could measure a low platelet count in Werlhof's disease but fiercely debated its cause. Was the marrow simply failing to make platelets, or was something in the blood destroying them after they were made? The question was settled by a now-legendary experiment performed in 1950 at Barnes Hospital in St. Louis by the young hematologist William J. Harrington and his colleague James W. Hollingsworth. Reasoning that ITP might be caused by a circulating factor in the patient's plasma, they decided to test it on a human being — and chose themselves. Because the transfused blood had to be compatible, they flipped, in effect, a genetic coin: of the two, Harrington's blood type matched the patient's, so Harrington became the subject.

Harrington had about 500 mL of blood transfused into himself from a patient with active ITP. The result was dramatic and frightening. Within roughly three hours his own platelet count collapsed to dangerously low levels; he suffered a seizure. His platelets remained critically low for several days — about four — before recovering to normal by the fifth day. A bone-marrow examination during the crisis showed that his megakaryocytes, the platelet-producing cells, were normal and even plentiful, proving the problem was not failed production but accelerated destruction. The experiment was then repeated on other willing hospital staff, who reproducibly developed transient thrombocytopenia after receiving ITP-patient blood.

The conclusion was inescapable: the blood of an ITP patient contains a circulating factor — soon understood to be an antiplatelet antibody — that destroys normal platelets. This proved that ITP is an immune disease, an autoimmune attack of the body on its own platelets, and it transformed the "I" in ITP over time from idiopathic (cause unknown) to immune. The findings were published in 1951 as Harrington, Minnich, Hollingsworth, and Moore, "Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura," in the Journal of Laboratory and Clinical Medicine. Beyond hematology, the experiment is celebrated as one of the first clear demonstrations that the immune system can target the body's own tissues, helping to launch the entire modern concept of autoimmune disease.

Back to Table of Contents

Sorting Out the Many Causes

Harrington proved that immune destruction is one route to a low platelet count, but the twentieth century steadily revealed that it is far from the only one. A central achievement of modern hematology has been to recognize that thrombocytopenia is a final common pathway reachable by several distinct mechanisms, each demanding a different response. The major categories now taught are immune destruction, drug-induced destruction, decreased marrow production, consumption within active clotting, and sequestration in the spleen.

Drug-induced thrombocytopenia emerged as its own important story. Quinine — long used for malaria and leg cramps — was among the first drugs recognized to trigger antibody-mediated platelet destruction, and the phenomenon of a medication provoking an immune attack on platelets is now well catalogued. A particularly dangerous and paradoxical variant, heparin-induced thrombocytopenia (HIT), was characterized in the later twentieth century: the blood-thinner heparin can, in some patients, provoke antibodies that both lower the platelet count and, alarmingly, drive clotting rather than bleeding. Decreased production — from leukemia, aplastic anemia, vitamin B12 or folate deficiency, certain viral infections, and especially the chemotherapy and radiation of cancer treatment — became increasingly prominent as those therapies came into wide use.

Two further mechanisms complete the picture. In consumption, platelets are used up faster than they can be replaced during widespread, inappropriate clotting; the prime example is disseminated intravascular coagulation (DIC), in which a low platelet count is a warning sign of a body-wide clotting catastrophe. In sequestration, the platelets exist but are pooled and trapped in an enlarged spleen (often from liver disease), lowering the count in the circulating blood even though total platelet mass may be near normal. The clinical art — built up case by case across the century — lies in telling these apart, because the treatment for an immune attack (suppress the immune system) is exactly wrong for marrow failure or splenic pooling.

Back to Table of Contents

Thrombopoietin and the Modern Era (1994–today)

One large piece of the puzzle remained until nearly the end of the twentieth century: what tells the body how many platelets to make? Researchers had long hypothesized a hormone — provisionally called thrombopoietin — that would regulate platelet production the way erythropoietin governs red cells, but for decades it remained an unproven idea. The breakthrough came in 1994, when several independent research groups, working in parallel and using the cell-surface receptor c-Mpl as the key, purified and cloned thrombopoietin (TPO) almost simultaneously. Landmark papers that year included de Sauvage and colleagues at Genentech in Nature and Lok, Kaushansky, and colleagues (also in Nature), among others — a striking instance of a long-sought molecule being captured by multiple teams at once.

Thrombopoietin proved to be the master regulator of platelet production: it is the hormone, made largely by the liver, that drives megakaryocytes to mature and release platelets, and it is essentially the only hormone that raises the platelet count from its baseline. Identifying it did more than complete the textbook diagram. It explained why diseases of the liver (which makes TPO) and of the marrow (which responds to it) cause thrombocytopenia, and — most importantly for patients — it opened a direct path to treatment by mimicking the hormone's action.

That path led to the TPO receptor agonists, a class of drugs that stimulate the c-Mpl receptor to boost platelet production. Romiplostim and eltrombopag, approved in 2008, were the first to reach patients and are now established treatments for chronic ITP and other forms of thrombocytopenia — the first therapies that work by telling the marrow to make more platelets rather than by suppressing their destruction. This modern, production-boosting strategy stands as the direct descendant of the 1994 discovery, and it complements the older immune-suppressing approaches that trace back to Harrington's proof that ITP is an antibody disease.

Back to Table of Contents

Legacy and What the History Teaches

The history of thrombocytopenia is a model of how medicine actually advances: a visible symptom is described long before its cause is known; a basic discovery (the platelet) gives the symptom a physical anchor; measurement (the platelet count) turns a vague category into a defined disorder; a daring experiment (Harrington's) reveals a mechanism; and molecular biology (thrombopoietin) finally yields targeted treatment. Each step took a tool the previous generation lacked — the intravital microscope, the counting chamber, the willingness to risk one's own body, the techniques of cloning — and each reframed an old illness as something newly understandable and, increasingly, treatable.

The story also carries a quiet caution that matters for anyone reading their own lab results. A low platelet count is not, by itself, a diagnosis; it is a signpost pointing toward many possible causes that look alike at the bedside but could not be more different beneath the surface — an immune attack, a drug reaction, a struggling marrow, a clotting emergency, a crowded spleen. The entire arc of this history is the slow, hard-won ability to tell those apart, because naming the right mechanism is what makes the right treatment possible. The discoveries of Werlhof, Bizzozero, Harrington, and the thrombopoietin pioneers are not museum pieces; they are the reason a person who bruises too easily today can be diagnosed precisely and helped.

For the modern clinical picture — symptoms, the specific causes, diagnosis, and current treatment — see the main Thrombocytopenia article, and the related hematology pages linked in the Connections section below.

Back to Table of Contents

Research Papers and References

The references below combine peer-reviewed historical reviews carrying real DOI or PMID identifiers with curated PubMed topic-search links into the primary literature on platelet discovery, the history of immune thrombocytopenia, and thrombopoietin. Where a named discoverer, date, or "first" appears in the article above, it has been checked against these sources. Historical figures named only as primary clinical observers — Paul Gottlieb Werlhof (1735) and Max Schultze (1865) — are cited here through the modern review literature that documents their priority. Each link opens at the publisher or at PubMed (National Library of Medicine) in a new tab.

  1. Ribatti D, Crivellato E. Giulio Bizzozero and the discovery of platelets. Leukemia Research. 2007;31(10):1339–1341. — doi:10.1016/j.leukres.2007.02.008 · PMID 17383722
  2. Brewer DB. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. British Journal of Haematology. 2006;133(3):251–258. — doi:10.1111/j.1365-2141.2006.06036.x · PMID 16643426
  3. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. Journal of Laboratory and Clinical Medicine. 1951;38(1):1–10. — PMID 14850832
  4. Stasi R, Newland AC. ITP: a historical perspective. British Journal of Haematology. 2011;153(4):437–450. — doi:10.1111/j.1365-2141.2010.08562.x
  5. Liebman HA. Immune thrombocytopenia (ITP): an historical perspective. Hematology Am Soc Hematol Educ Program. 2008;2008(1):205–206. — doi:10.1182/asheducation-2008.1.205
  6. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533–538. — doi:10.1038/369533a0 · PMID 8202154
  7. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369(6481):565–568. — doi:10.1038/369565a0
  8. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. International Journal of Hematology. 2013;98(1):10–23. — doi:10.1007/s12185-013-1382-0
  9. Coller BS. Historical perspective and future directions in platelet research. Journal of Thrombosis and Haemostasis. 2011;9(Suppl 1):374–395. — doi:10.1111/j.1538-7836.2011.04356.x
  10. History of platelet discovery and Giulio Bizzozero — PubMed: Bizzozero platelet discovery history
  11. History of immune thrombocytopenia (Werlhof's disease) — PubMed: immune thrombocytopenia Werlhof history
  12. Harrington self-experiment and antiplatelet factor in ITP — PubMed: Harrington thrombocytopenic factor in ITP
  13. Thrombopoietin discovery, cloning, and c-Mpl ligand — PubMed: thrombopoietin cloning c-Mpl ligand
  14. Drug-induced and heparin-induced thrombocytopenia — PubMed: drug-induced and heparin-induced thrombocytopenia

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents